Table 4.

Overview of the biodistribution of ²²³Ra after intravenous injection in patients from four clinical trials [8, 10, 11, 17] in comparison to the modelled data of the present work; data expressed as percentage of administered ²²³Ra; values given as range, median or mean ± SD; n = patient number

Region	Time post-injection	Present work	Nilsson et al. [17] n = 25	Carrasquillo et al. [11] n = 10	Chittenden et al. [10] n = 6	Yoshida et al. [8] n = 6
Plasma	10-15 min	55	12			9-28 (22)
	4 h	2.0		1.6-3.9 (2)		1-6 (4)
	24 h	0.5	< 1	0.37-1.0 (0.55)	0.6-5.1 (1.1)
	3 d	0.2				0-0.9 (0.3)
Bonea	2 h	28.2				41-57 (52)
	4 h	29.8			61 ± 10
Urine (cumulative)	4 h	0.83		5 (first void)
	2 d	1.58			2 ± 2	2
Faeces (cumulative)	1 d	12.9		40-61 (52)
	2 d	35.3			13 ± 12
	3 d	47.4				29-95 (64)
	7 d	52.1			60-80
RC/ULI* content	1 d	11.6			45 ± 16
	7 d	0.53			0-18 (4)
LC/LLI** content	2 d	7.4			17 ± 11
	7 d	0.64			6 ± 4
HATM/GI tract*** content	6 h	40.9				22-85 (64)
	1 d	39.3		50.8 ± 7.5		32-78 (52)
	2 d	22.0				4-76 (31)
	3 d	11.8				5-53 (21)
	7-8 d	1.9				0-9 (3)

^aTotal bone, i.e. surface, volume and bone marrow

*RC/ULI, right colon/upper large intestine

**LC/LLI, left colon/lower large intestine

***HATM, human alimentary tract model (HATM) [21] referring in the present model to the RC, LC and recto sigmoid; GI tract, gastrointestinal tract (ICRP 30, [26]) representing small intestine, ULI and LLI. The present work refers to RC/LC/HATM content, whereas the clinical studies refer to ULI/LLI/GI tract content